Literature DB >> 25530923

Implications of Mesenchymal Cells in Cancer Stem Cell Populations: Relevance to EMT.

Amy N Abell1, Gary L Johnson2.   

Abstract

The epithelial to mesenchymal transition (EMT) generates tumor cells having stem cell characteristics with phenotypes similar to cancer stem cells (CSCs). Evidence suggests CSCs are in an intermediate state of EMT expressing reduced levels of E-cadherin and exhibiting mesenchymal features including invasiveness associated with metastasis. These findings suggest mechanisms regulating EMT and stemness are closely integrated. Recent reports from multiple laboratories have identified novel mechanisms regulating EMT and stemness involving epigenetics, microenvironment, and dedifferentiation. Circulating tumor cells (CTCs) have also been shown to exhibit features of EMT, but it is unclear what fraction has CSCs properties. EMT characteristics of both CSCs and CTCs are associated with resistance to current clinical treatments, indicating therapies targeting the CSC in addition to the more differentiated tumor cells are required for durable responses. Thus, EMT characteristics of CTCs may prove useful biomarkers for effective therapies for many cancers.

Entities:  

Keywords:  EMT; cancer stem cells (CSCs); cell plasticity; circulating tumor cells (CTCs); epigenetics

Year:  2014        PMID: 25530923      PMCID: PMC4266994          DOI: 10.1007/s40139-013-0034-7

Source DB:  PubMed          Journal:  Curr Pathobiol Rep        ISSN: 2167-485X


  26 in total

Review 1.  EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer.

Authors:  A Singh; J Settleman
Journal:  Oncogene       Date:  2010-06-07       Impact factor: 9.867

Review 2.  The mesenchymal cell, its role in the embryo, and the remarkable signaling mechanisms that create it.

Authors:  Elizabeth D Hay
Journal:  Dev Dyn       Date:  2005-07       Impact factor: 3.780

3.  Normal and neoplastic nonstem cells can spontaneously convert to a stem-like state.

Authors:  Christine L Chaffer; Ines Brueckmann; Christina Scheel; Alicia J Kaestli; Paul A Wiggins; Leonardo O Rodrigues; Mary Brooks; Ferenc Reinhardt; Ying Su; Kornelia Polyak; Lisa M Arendt; Charlotte Kuperwasser; Brian Bierie; Robert A Weinberg
Journal:  Proc Natl Acad Sci U S A       Date:  2011-04-15       Impact factor: 11.205

Review 4.  Epithelial-mesenchymal transitions in development and disease.

Authors:  Jean Paul Thiery; Hervé Acloque; Ruby Y J Huang; M Angela Nieto
Journal:  Cell       Date:  2009-11-25       Impact factor: 41.582

Review 5.  Cancer stem cells: current status and evolving complexities.

Authors:  Jane E Visvader; Geoffrey J Lindeman
Journal:  Cell Stem Cell       Date:  2012-06-14       Impact factor: 24.633

6.  Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features.

Authors:  Chad J Creighton; Xiaoxian Li; Melissa Landis; J Michael Dixon; Veronique M Neumeister; Ashley Sjolund; David L Rimm; Helen Wong; Angel Rodriguez; Jason I Herschkowitz; Cheng Fan; Xiaomei Zhang; Xiaping He; Anne Pavlick; M Carolina Gutierrez; Lorna Renshaw; Alexey A Larionov; Dana Faratian; Susan G Hilsenbeck; Charles M Perou; Michael T Lewis; Jeffrey M Rosen; Jenny C Chang
Journal:  Proc Natl Acad Sci U S A       Date:  2009-08-03       Impact factor: 11.205

7.  Wnt activity defines colon cancer stem cells and is regulated by the microenvironment.

Authors:  Louis Vermeulen; Felipe De Sousa E Melo; Maartje van der Heijden; Kate Cameron; Joan H de Jong; Tijana Borovski; Jurriaan B Tuynman; Matilde Todaro; Christian Merz; Hans Rodermond; Martin R Sprick; Kristel Kemper; Dick J Richel; Giorgio Stassi; Jan Paul Medema
Journal:  Nat Cell Biol       Date:  2010-04-25       Impact factor: 28.824

8.  SWI/SNF chromatin-remodeling factor Smarcd3/Baf60c controls epithelial-mesenchymal transition by inducing Wnt5a signaling.

Authors:  Nicole Vincent Jordan; Aleix Prat; Amy N Abell; Jon S Zawistowski; Noah Sciaky; Olga A Karginova; Bingying Zhou; Brian T Golitz; Charles M Perou; Gary L Johnson
Journal:  Mol Cell Biol       Date:  2013-05-28       Impact factor: 4.272

9.  The epithelial-mesenchymal transition generates cells with properties of stem cells.

Authors:  Sendurai A Mani; Wenjun Guo; Mai-Jing Liao; Elinor Ng Eaton; Ayyakkannu Ayyanan; Alicia Y Zhou; Mary Brooks; Ferenc Reinhard; Cheng Cheng Zhang; Michail Shipitsin; Lauren L Campbell; Kornelia Polyak; Cathrin Brisken; Jing Yang; Robert A Weinberg
Journal:  Cell       Date:  2008-05-16       Impact factor: 41.582

Review 10.  The basics of epithelial-mesenchymal transition.

Authors:  Raghu Kalluri; Robert A Weinberg
Journal:  J Clin Invest       Date:  2009-06       Impact factor: 14.808

View more
  23 in total

1.  Aldehyde dehydrogenases in cancer stem cells: potential as therapeutic targets.

Authors:  David W Clark; Komaraiah Palle
Journal:  Ann Transl Med       Date:  2016-12

2.  Gastric tumor-initiating CD44+ cells and epithelial-mesenchymal transition are inhibited by γ-secretase inhibitor DAPT.

Authors:  Lu-Chun Li; Dong-Lin Wang; Yong-Zhong Wu; Wei-Qi Nian; Zhi-Juan Wu; Yan Li; Hui-Wen Ma; Jiang-He Shao
Journal:  Oncol Lett       Date:  2015-09-18       Impact factor: 2.967

3.  Controlling Epithelial to Mesenchymal Transition through Acetylation of Histone H2BK5.

Authors:  Robert J Mobley; Amy N Abell
Journal:  J Nat Sci       Date:  2017-09

4.  Relevance of A Disintegrin and Metalloproteinase Domain-Containing (ADAM)9 Protein Expression to Bladder Cancer Malignancy.

Authors:  Michika Moriwaki; Trang Thi-Huynh Le; Shian-Ying Sung; Yura Jotatsu; Youngmin Yang; Yuto Hirata; Aya Ishii; Yi-Te Chiang; Kuan-Chou Chen; Katsumi Shigemura; Masato Fujisawa
Journal:  Biomolecules       Date:  2022-06-06

5.  E-Cadherin repression increases amount of cancer stem cells in human A549 lung adenocarcinoma and stimulates tumor growth.

Authors:  M Farmakovskaya; N Khromova; V Rybko; V Dugina; B Kopnin; P Kopnin
Journal:  Cell Cycle       Date:  2016       Impact factor: 4.534

6.  Epithelial Mesenchymal Transition: a double-edged sword.

Authors:  Guislaine Barriere; Pietro Fici; Giulia Gallerani; Francesco Fabbri; Michel Rigaud
Journal:  Clin Transl Med       Date:  2015-04-14

Review 7.  Current understanding of epigenetics mechanism as a novel target in reducing cancer stem cells resistance.

Authors:  Saeedeh Keyvani-Ghamsari; Khatereh Khorsandi; Azhar Rasul; Muhammad Khatir Zaman
Journal:  Clin Epigenetics       Date:  2021-05-29       Impact factor: 6.551

8.  A novel screening approach comparing kinase activity of small molecule inhibitors with similar molecular structures and distinct biologic effects in triple-negative breast cancer to identify targetable signaling pathways.

Authors:  Margarite D Matossian; Hope E Burks; Steven Elliott; Van T Hoang; William J Zuercher; Carrow Wells; David H Drewry; Nirav Kapadia; Tiffany Chang; Thomas Yan; Gabrielle O Windsor; Khoa Nguyen; Fang Fang; Kenneth P Nephew; Aaron Buechlein; Douglas B Rusch; Rachel A Sabol; Deniz A Ucar; Jovanny Zabaleta; Lucio Miele; Bruce A Bunnell; Bridgette M Collins-Burow; Matthew E Burow
Journal:  Anticancer Drugs       Date:  2020-09       Impact factor: 2.389

Review 9.  Cancer Stem Cells: The Potential Targets of Chinese Medicines and Their Active Compounds.

Authors:  Ming Hong; Hor Yue Tan; Sha Li; Fan Cheung; Ning Wang; Tadashi Nagamatsu; Yibin Feng
Journal:  Int J Mol Sci       Date:  2016-06-07       Impact factor: 5.923

10.  1α,25(OH)₂D₃ Suppresses the Migration of Ovarian Cancer SKOV-3 Cells through the Inhibition of Epithelial-Mesenchymal Transition.

Authors:  Yong-Feng Hou; Si-Hai Gao; Ping Wang; He-Mei Zhang; Li-Zhi Liu; Meng-Xuan Ye; Guang-Ming Zhou; Zeng-Li Zhang; Bing-Yan Li
Journal:  Int J Mol Sci       Date:  2016-08-19       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.